XOMAO
XOMA Corporation NASDAQ Listed Apr 12, 2021$24.97
-1.94%
vs $25.46
Mkt Cap $539.3M
52w Low $24.86
7.1% of range
52w High $26.40
50d MA $25.34
200d MA $25.43
P/E (TTM)
17.1x
EV/EBITDA
9.6x
P/B
4.3x
Debt/Equity
1.3x
ROE
37.8%
P/FCF
156.4x
RSI (14)
18.50
ATR (14)
$0.04
Beta
0.68
50d MA
$25.34
200d MA
$25.43
Avg Volume
5.4K
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
2200 Powell Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.11 | 0.26 | +327.0% | 25.44 | -0.7% | -0.4% | -0.0% | +0.3% | +0.0% | +0.0% | — |
| Nov 12, 2025 | AMC | -0.04 | 0.78 | +2037.5% | 25.44 | +0.2% | -0.0% | +0.3% | -0.5% | +0.1% | +0.3% | — |
| Aug 15, 2025 | AMC | -0.15 | 0.52 | +444.7% | 25.45 | -0.1% | -0.1% | -0.2% | -0.2% | +1.0% | -0.7% | — |
| May 13, 2025 | AMC | -0.24 | 0.20 | +183.2% | 25.04 | +0.0% | +0.0% | -0.0% | +0.1% | +1.0% | -0.2% | — |
| Mar 17, 2025 | AMC | -0.29 | -0.33 | -16.5% | 25.41 | -0.3% | -0.4% | -0.2% | +0.8% | -0.1% | +0.0% | — |
| Nov 7, 2024 | AMC | — | -1.47 | — | 25.55 | -0.1% | +0.2% | +0.0% | -0.2% | +0.1% | -0.2% | — |
| Aug 13, 2024 | AMC | — | 0.92 | — | 25.15 | -1.0% | +0.0% | -0.6% | -0.1% | +0.5% | +0.3% | — |
| May 9, 2024 | AMC | — | -0.74 | — | 25.12 | -0.1% | -0.1% | +0.6% | -0.4% | +0.4% | -0.6% | — |
| Mar 8, 2024 | AMC | — | -1.75 | — | 24.86 | -0.0% | +0.5% | +0.0% | -0.2% | +0.3% | +0.3% | — |
| Mar 6, 2024 | AMC | — | -0.48 | — | 24.50 | +0.4% | +1.0% | +0.4% | +0.5% | +0.0% | -0.2% | — |
| Aug 8, 2023 | AMC | — | -0.47 | — | 23.77 | +0.1% | +1.8% | +0.0% | -0.2% | +0.2% | +0.0% | — |
| May 9, 2023 | AMC | — | -1.55 | — | 23.21 | -0.5% | -0.5% | -1.3% | +2.6% | -2.1% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.37 | $23.44 | +0.3% | +1.4% | -0.4% | +1.3% | +1.1% | -0.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.94 | $23.97 | +0.1% | -0.7% | +1.8% | +0.0% | -0.2% | +0.2% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.85 | $23.99 | +0.6% | +0.5% | +1.1% | -0.4% | +0.4% | +0.3% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.55 | $23.54 | -0.0% | -0.2% | -0.2% | +0.6% | +1.1% | +0.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.84 | $24.84 | +0.0% | -2.1% | -0.7% | +0.2% | -2.4% | +0.1% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.17 | $26.24 | +0.3% | +0.5% | -0.1% | -0.4% | -0.3% | +0.2% |
| Sep 8 | Aegis Capital | Maintains | Buy → Buy | — | $26.50 | $26.43 | -0.3% | -0.9% | +0.8% | -0.1% | +1.2% | -0.1% |
| Sep 6 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 29 | Aegis Capital | Maintains | Buy → Buy | — | $25.15 | $25.17 | +0.1% | +0.1% | +0.5% | -0.9% | -0.1% | +0.4% |
| Sep 4 | Wedbush | Upgrade | Neutral → Outperform | — | — | — | — | — | — | — | — | — |
| Jun 12 | H.C. Wainwright | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 27 | Wedbush | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 13 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Jul 22 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 28 | Susquehanna | Downgrade | Positive → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 11 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Nov 9 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Apr 28 | McNicoll Lewis Vlak | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 10 | McNicoll Lewis Vlak | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Mar 4 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 4 | Credit Suisse | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| May 8 | Canaccord Genuity | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Jan 6 | Wedbush | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 8 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 19 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
No recent filings available.
Valuation
Market Cap
$539.3M
Enterprise Value
$482.7M
P/E (TTM)
17.11x
Forward P/E
22.22x
PEG Ratio
-0.08x
P/B
4.32x
P/S
14.88x
P/FCF
156.40x
EV/EBITDA
9.62x
Shares Out
18.0M
Financials (TTM)
Revenue
$36.2M
Net Income
$31.5M
EBITDA
$50.2M
Free Cash Flow
$2.9M
Op Cash Flow
$2.9M
EPS Basic
$1.53
EPS Diluted
$1.57
EPS Forward
$1.12
Gross Margin
93.3%
Op Margin
13.7%
Net Margin
87.0%
Balance Sheet
Total Assets
$272.7M
Total Liab.
$168.7M
Total Equity
$104.0M
Cash
$82.9M
LT Debt
$116.6M
Book Value/Sh
$5.78
Debt/Equity
1.27x
Current Ratio
3.37
Quick Ratio
3.37
Returns & Growth
ROE
37.8%
ROA
11.6%
ROIC
4.5%
Rev Growth YoY
+83.1%
EPS Growth YoY
+192.7%
Price Returns
2W
-1.7%
1M
-1.5%
3M
-4.9%
6M
-1.2%
12M
-1.1%
Technicals
52W High
$26.40
52W Low
$24.86
50d MA
$25.34
200d MA
$25.43
RSI (14)
18.50
ATR (14)
$0.04
Beta
0.68
Avg Volume
5K
Dividends
Div Rate
$0.30
Div Yield
1.2%
Frequency
4
Ex-Div Date
Apr 2, 2026
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 10:41am
· Source: financialmodelingprep.com